{"first_name":"Christopher","last_name":"Meldrum","permalink":"christopher-meldrum","crunchbase_url":"http://www.crunchbase.com/person/christopher-meldrum","homepage_url":null,"birthplace":null,"twitter_username":null,"blog_url":null,"blog_feed_url":null,"affiliation_name":"Unaffiliated","born_year":null,"born_month":null,"born_day":null,"tag_list":null,"alias_list":null,"created_at":"Sun Jun 21 08:22:25 UTC 2009","updated_at":"Sun Jun 21 08:42:45 UTC 2009","overview":"<p>Mr. Meldrum serves as Chairman of the Board of Directors for Kylin. Mr. Meldrum is Managing Director at Golden Pine Ventures, and has worked extensively with development-stage biotechnology and medical device companies, founding and helping to secure financing for seven biomedical start-up ventures. Mr. Meldrum also currently serves as President and a Director of Pique Therapeutics, a biotechnology company focused in oncology, with a lead product in Phase II clinical trials. </p>\n\n<p>Before joining Golden Pine Ventures in 2004, Mr. Meldrum was Director, Corporate Alliances, at Paradigm Genetics, a publicly-traded biotechnology company, where he led business development efforts for both the healthcare and agriculture businesses.  He held business development positions of increasing responsibility since joining the company in the summer of 2000.  During his time at Paradigm, he negotiated to completion seven revenue-generating collaborations with deal values totaling over $30 million. </p>\n\n<p>Before his time at Paradigm, Mr. Meldrum worked as Licensing Associate for Purdue University, where he managed the out-licensing of Purdue&#8217;s biotechnology and life sciences portfolio.  Prior to his time at Purdue, he worked for two years in the University of Minnesota&#8217;s technology transfer office.  Over the course of his career, he has successfully led negotiations for more than 70 fully-executed deals. </p>\n\n<p>Mr. Meldrum received his MBA from the Carlson School of Management at the University of Minnesota and his B.A. in Chemistry from the University of Utah. </p>\n\n<p>Company\nOverview</p>","image":{"available_sizes":[[[85,100],"assets/images/resized/0004/9960/49960v1-max-150x150.jpg"],[[85,100],"assets/images/resized/0004/9960/49960v1-max-250x250.jpg"],[[85,100],"assets/images/resized/0004/9960/49960v1-max-450x450.jpg"]],"attribution":""},"degrees":[],"relationships":[{"is_past":false,"title":"Chairman","firm":{"name":"Kylin Therapeutics","permalink":"kylin-therapeutics","type_of_entity":"company","image":{"available_sizes":[[[150,90],"assets/images/resized/0004/9954/49954v1-max-150x150.png"],[[166,100],"assets/images/resized/0004/9954/49954v1-max-250x250.png"],[[166,100],"assets/images/resized/0004/9954/49954v1-max-450x450.png"]],"attribution":null}}},{"is_past":false,"title":"Managing Director ","firm":{"name":"Golden Pine Ventures","permalink":"golden-pine-ventures","type_of_entity":"financial_org","image":{"available_sizes":[[[150,38],"assets/images/resized/0004/9957/49957v2-max-150x150.png"],[[250,64],"assets/images/resized/0004/9957/49957v2-max-250x250.png"],[[450,116],"assets/images/resized/0004/9957/49957v2-max-450x450.png"]],"attribution":null}}}],"investments":[],"milestones":[],"video_embeds":[],"external_links":[],"web_presences":[]}